Nominations for the 2021 Dr. Paul Janssen Awards: #DPJAwards
Honoring scientists who have significantly impacted human health—are live through February 28. If a scientist has made a significant, transformational contribution, nominate them here.
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination
Johnson & Johnson Innovation - JLABS Year in Review Spotlights Resilience of Global Ecosystem
Johnson & Johnson Innovation – JLABS Global Head Melinda Richter discusses how the JLABS ecosystem sought to meet the moment, emphasizing the work of JLABS companies aiming to find potential COVID-19 solutions, as well as the importance of fostering diversity and inclusion and addressing health inequities.